USA-based Allergan (NYSE: AGN) reported financial results for the first quarter of 2012, with diluted earnings rocketing 45% to $230.3 million, or $0.74 per share, compared with $0.51 a share in the kike, year-earlier period. Excluding acquisition and restructuring charges and other items, earnings per share were up 11.7% at $0.86. Allergan reported $1.37 billion total product net sales, a rise of 9.0%.
For the full year of 2012, all expectations provided in February remain unchanged. For the second quarter of 2012, Allergan expects: total product net sales of between $1.45 billion and $1.50 billion; and non-GAAP diluted earnings per share attributable to stockholders between $1.04 and $1.06. Analysts polled by Thomson Reuters most recently expected $1.51 billion and $1.08, respectively
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze